All In Biotech

Drug Trial Radar · NCT06608927

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 610 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

610

Planned (sponsor's estimate)

Start

Dec 13, 2024

Primary completion

Nov 30, 2030

Study completion Nov 30, 2030

Sponsor

Lead sponsor
Arcus Biosciences, Inc.Industry
Sponsor type
Industry
Collaborators
Taiho Pharmaceutical Co., Ltd.
First posted
Sep 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.

Conditions

  • Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

  • QuemliclustatDrug

    Administered as specified in the treatment arm

  • PlaceboDrug

    Administered as specified in the treatment arm

  • Nab-paclitaxelDrug

    Administered as specified in the treatment arm

  • GemcitabineDrug

    Administered as specified in the treatment arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to 72 months

Locations

111 sites in 13 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    La Jolla, California

  • Research Site

    Los Alamitos, California

  • Research Site

    Los Angeles, California

  • Research Site

    Roseville, California

  • Research Site

    San Francisco, California

  • Research Site

    Santa Monica, California

  • Research Site

    Denver, Colorado

  • Research Site

    New Haven, Connecticut

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Arlington Heights, Illinois

  • Research Site

    Chicago, Illinois

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Wichita, Kansas

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Rochester, Minnesota

  • Research Site

    Hattiesburg, Mississippi

  • Research Site

    Kansas City, Missouri

  • Research Site

    Omaha, Nebraska

  • Research Site

    New Brunswick, New Jersey

  • Research Site

    Buffalo, New York

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Rochester, New York

  • Research Site

    Cleveland, Ohio

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Nashville, Tennessee

  • Research Site

    Austin, Texas

  • Research Site

    Dallas, Texas

Showing 40 of 111 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.